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Abstract: The 2015 Gastrointestinal Cancers Symposium (San Francisco, CA, USA; January 
15–17) is the world-class conference co-sponsored by the American Society of Clinical Oncol-
ogy, the American Society for Radiation Oncology, the American Gastroenterological Asso-
ciation Institute, and the Society of Surgical Oncology, in which the most innovative research 
results in digestive tract oncology are presented and discussed. In its twelfth edition, the meeting 
has provided new insights focusing on the underpinning biology and clinical management of 
gastrointestinal malignancies. More than 3,400 health care professionals gathered from all over 
the world to share their experiences on how to bridge the recent novelties in cancer biology with 
everyday medical practice. In this article, the authors report on the most significant advances, 
didactically moving on three different anatomic tracks: gastroesophageal malignancies, pan-
creatic and biliary cancers, and colorectal adenocarcinomas.
Keywords: colorectal cancer, gastric cancer, ramucirumab, pembrolizumab, target therapy, 
onartuzumab, AMG 337
Introduction
Significant studies have been presented at the 2015 Gastrointestinal Cancers Symposium, 
an outstanding appointment that is held every January in San Francisco, CA, USA. 
Although this year the practice-changing results were limited, results of many studies 
have markedly contributed to the expansion of our knowledge in the biology of gas-
trointestinal malignancies and to fine-tune the available treatment options.
Aims of this report are to recall and comment on the most significant preclinical and 
clinical studies that have been presented at the scientific venue, which will continue 
the major progress made in the past decades.1 In the gastroesophageal track, we will 
present and reason on the available results of the studies testing mesenchymal epithelial 
transition (MET) factor inhibitors (AMG 337 and onartuzumab) and programmed cell 
death receptor 1 ligand (PD-L1) inhibitors (pembrolizumab) in patients with upper 
gastrointestinal tract diseases. In the second section of the manuscript, we will describe 
how a comprehensive molecular profiling of biliary tract cancers may be used as a 
tool for treatment and prognostic stratification, update on the method for refining 
optimal candidates for sorafenib in hepatocellular carcinoma (HCC), and discuss how 
to expand valuable treatment options in pancreatic carcinomas, including the novel 
MM-398 and PF-04136309. In the final section focused on colorectal cancers (CRCs), 
we will face the most recent advances in molecular selection for targeted therapies 
and understand that CRC has many underlying drivers, as well as the opportunity to 
identify targets responsible for drug resistance and the possibility of reshaping the 
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paradigm of sequential approach in multimodality therapies. 
Notable advances that may challenge the current paradigms in 
the management of rectal cancers are also presented. Results 
are summarized in Table 1.
Steps ahead in upper 
gastrointestinal malignancies
Recent advances in the understanding of gastric cancer biol-
ogy and the comprehensive molecular analysis performed 
by the Cancer Genome Atlas (TCGA), which allowed 
recognizing four distinct disease subtypes,2 have served as 
the rationale for the development of novel targeted agents.3 
Overexpression or amplification of the MET factor has been 
observed in gastric cancer4 and been correlated with unfa-
vorable clinical outcomes.5 Compared to the proportion of 
genes identified by immunohistochemical (IHC) detection of 
overexpression, the rate of detection of activating mutations 
or amplifications of MET gene is higher,6 defining a small 
group of tumors with aggressive clinical behavior regardless 
of disease stage. AMG 337 is a highly selective, orally avail-
able MET inhibitor that showed promising preclinical activ-
ity. In a multicenter, Phase I, open-label trial, 80 patients with 
MET-amplified tumors and good performance status (PS) 
received increasing doses of AMG 337 monotherapy, defin-
ing 300 mg/day as the maximum tolerated dose.7 In the small 
subset of 13 heavily pretreated patients with MET-amplified 
gastroesophageal tumors exposed to AMG 337, the investiga-
tors observed a notable 62% rate of response. Interestingly, 
the response was fast and usually detectable within 4 weeks 
from treatment start, which may be a remarkable advantage 
for symptomatic patients. The experimental treatment had 
a favorable profile of tolerability. Dose-limiting toxicities 
were severe hypertension, headache, and increased amylase 
activity; the most common side effects were headache (45%), 
nausea (32%), vomiting (21%), fatigue (14%), and peripheral 
edema (12%); headache (9%) and fatigue (4.5%) were the 
most frequent severe adverse events.
Onartuzumab is a recombinant, fully humanized, mono-
clonal anti-MET antibody. Results of the randomized Phase II 
trial testing upfront FOLFOX6 with onartuzumab at the dose 
of 10 mg/kg or FOLFOX6 plus placebo were presented.8 
One hundred and twenty-three patients with advanced 
gastroesophageal cancer were enrolled from 25 centers; 
key eligibility criteria included no previous treatments for 
metastatic disease, Eastern Cooperative Oncology Group 
(ECOG) PS status of 0 or 1, and retention of organ func-
tion. MET-positive patients, defined as those with 50% of 
tumor with moderate–strong intensity staining by centrally 
reviewed IHC, were well balanced in the two arms: 28% in 
the experimental arm vs 33% in the control arm. Stratifica-
tion factors were histological subtype and previous gastrec-
tomy. At data cutoff, 96 out of 121 randomized patients had 
progression-free survival (PFS) events, 74% of those exposed 
to FOLFOX and onartuzumab and 82% of those receiving 
FOLFOX and placebo. The primary end point, PFS, in the 
intention-to treat population, was not met (6.77 months in the 
onartuzumab arm, 6.97 months in the placebo arm; hazard 
ratio [HR]: 1.08, 95% confidence interval [CI]: 0.71–1.63). 
In addition, the preplanned analyses in the MET-positive 
population generated similarly disappointing results: median 
PFS was 5.95 months for those exposed to FOLFOX6 and 
onartuzumab vs 6.8 months for those treated with FOL-
FOX6 and placebo (HR: 1.38). No differences were found 
despite the use of different definitions for MET positivity. 
Table 1 Significant clinical trials presented at the Gastrointestinal Cancers Symposium 2015 investigating novel agents in gastric, liver, 
and colorectal carcinomas
Authors Phase Treatment line Design Primary end point Trial outcome
Kwak et al7 I Refractory AMG 337, single arm Safety Good tolerance, RR: 62%
Shah et al8 II, randomized First-line FOLFOX ± onartuzumab PFS HR
Zhu et al22 III, randomized Second-line Ramucirumab vs placebo OS HR: 0.67; (95% CI:  
0.51–0.90*; P=0.0059)
Cheng et al24 II, randomized First-line Dovitinib vs sorafenib OS HR: 1.27; 95% CI: 
0.89–1.80; P=ns
Palmer et al25 II, randomized First-line Nintedanib vs sorafenib TTP HR: 1.05; 95% CI:  
0.63–1.76; P=ns
Tabernero et al34 III, randomized Second-line FOLFIRI + ramucirumab  
vs FOLFIRI + placebo
OS HR: 0.84; (95% CI:  
0.73, 0.98); P=0.0219
Xu et al35 II, randomized Refractory Famitinib vs placebo PFS HR: 0.58; P=0.0034
Notes: *A prespecified subgroup analysis according to baseline alpha-fetoprotein (AFP) level suggested that patients with baseline AFP 400 ng/mL might derive benefit from 
ramucirumab treatment vs placebo (OS HR: 0.67, 95% CI: 0.51–0.90; P=0.0059).
Abbreviations: CI, confidence interval; HR, hazard ratio; ns, nonsignificant; OS, median overall survival; PFS, progression-free survival; RR, response rate; TTP, time to 
progression.
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The addition of onartuzumab was not beneficial, regardless 
of patients’ race, and produced more adverse events. It is 
unclear whether these negative results suggest a failure of 
the strategy or the unreliability of the current definition of 
MET positivity. In fact, while it is reasonable not to consider 
IHC MET overexpression a good driver for patient selection, 
it should also be recalled that a large Phase III trial testing 
onartuzumab was prematurely interrupted because of failure 
of the drug in lung cancers,9 and another randomized study 
testing rilotumumab in the advanced disease setting failed 
to meet the primary trial end point.10
Targeting the immune checkpoints in solid malig-
nancies is becoming a major methodological approach. 
T-lymphocytes may recognize and eliminate cancer antigens, 
while immune checkpoints such as cytotoxic T-lymphocyte-
associated antigen (CTLA)-4 and programmed cell death 
(PD-1) receptor and its ligands (PD-L1, PD-L2) are able to 
suppress the activity of T-lymphocytes. Therefore, enhancing 
antitumor immunity by blocking PD-1 is now an attractive 
reality. Pembrolizumab, a highly selective IgG4k, humanized 
monoclonal antibody against PD-1, has recently received 
approval from the US Food and Drug Administration for the 
treatment of advanced melanoma after the failure of ipili-
mumab administration or BRAF V600E-mutant melanoma 
in progression following BRAF inhibitor administration.11 
Because the high expression of PD-L1 on tumor gastric 
cells12 and macrophages can suppress immune surveillance 
and permit neoplastic growth,13 the molecule has become 
an interesting target even in gastric cancer. Preliminary 
data of the KEYNOTE-012 gastric cohort study, in which 
pembrolizumab (MK-3475) was given at 10 mg/kg every 
2 weeks to 39 patients with PD-L1-positive advance gastric 
cancer, were recently presented.14 The trial enrolled heavily 
pretreated Asian (19) or non-Asian (20) patients, wherein 
67% received 2 treatment lines. Overall response rate 
(RR) was 30.8% (95% CI: 17.0–46.6) and 41% of patients 
experienced a decrease in tumor burden. Aim of the abstract 
presented at the 2015 Gastrointestinal Cancers Symposium 
was to analyze the relationship between PD-L1 expression 
and clinical outcome in patients with advanced disease 
treated with pembrolizumab.15 Muro et al15 found a sig-
nificant association between PD-L1 expression level and 
objective response rate (ORR; one-sided P=0.10). Median 
overall survival (OS) was not reached, but the 6-month OS 
rate was surprisingly high (69%). Though described as eas-
ily manageable by the authors, the toxicity profile appears a 
bit challenging, with five severe adverse events (peripheral 
sensory neuropathy, fatigue, decreased appetite, hypoxia, and 
pneumonitis) and one drug-related death (hypoxia). Because 
the immune-related response may not be fully captured by 
conventional response criteria,16 it would be interesting to 
assess the response with immune-related response criteria 
to further confirm the activity of pembrolizumab. On the 
basis of the KEYNOTE results, a Phase III randomized trial 
that compares pembrolizumab to paclitaxel in patients with 
recurrent or metastatic gastric or gastroesophageal junction 
adenocarcinoma who progressed after first-line treatment 
has been planned.
Perioperative chemotherapy is a standard of care in 
locally advanced gastroesophageal cancer in Europe.17,18 
In the MAGIC population, the human epidermal growth 
factor receptor 2 (HER2) positivity was not a prognostic or 
predictive factor.19 In the NEOHX study,20 36 patients with 
HER2-positive locally advanced gastric adenocarcinoma 
entered the Phase II trial to explore the combination of 
trastuzumab and chemotherapy in this setting. Patients were 
treated with three preoperative cycles of standard XELOX 
plus trastuzumab (loading dose 8 mg/kg, instead of 6 mg/kg), 
followed by definitive surgery. In the postoperative phase, 
patients received three other cycles of the same combination 
regimen and eventually 12 cycles of trastuzumab mono-
therapy. The primary end point of the study was 18 months 
disease-free survival (DFS). Median age at trial entry was 
63 years. R0 resection was reached in 78% of the patients 
(three cases had a pathological complete response), median 
DFS rate at 18 months was 71%, 2-year OS rate was 75%, 
while median DFS and OS had not been reached. The trial 
results are very interesting in this biologically selected popu-
lation and may promote the use of trastuzumab in resectable 
gastric cancer patients.
Significant advances in HCC, 
pancreatic cancer, and ciliary  
tract adenocarcinoma
Ramucirumab is a humanized monoclonal antibody that 
specifically blocks the vascular endothelial growth factor 
receptor 2 (VEGFR2).21 The REACH trial is a random-
ized Phase III study investigating ramucirumab as a single 
agent for the treatment of advanced HCC after failure of 
first-line sorafenib.22 Unfortunately, the trial did not meet 
its primary end point. In fact, median OS was 9.2 months 
for ramucirumab vs 7.6 months for placebo. Interestingly 
the prespecified subgroup analysis suggested that baseline 
alpha-fetoprotein (AFP) level might be a predictive marker 
for ramucirumab efficacy. Among 250 patients with baseline 
AFP 400 ng/mL, OS HR was 0.67 (95% CI: 0.51–0.90; 
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P=0.0059) (Table 1). Median OS was 7.8 months for 
ramucirumab vs 4.2 months for placebo. Accordingly, in 
patients with a baseline AFP 1.5× the upper limit, OS was 
8.6 months for ramucirumab vs 5.7 months for placebo and 
the HR was 0.749 (95% CI: 0.603–0.930; P=0.0088). In the 
REACH trial, AFP baseline levels seemed to be correlated 
with clinical outcome during ramucirumab treatment. Hope-
fully, the impact of this novel treatment approach will be 
proved prospectively in future clinical trials incorporating 
findings from the REACH study.
Casadei Gardini et al23 presented a new prognostic factor 
for advanced HCC patients receiving sorafenib. The authors 
hypothesized that the antiangiogenic compound might induce 
an inhibition of endothelial nitric oxide synthase (eNOS) 
activity by blocking the VEGFRs, with a consequent decrease 
of the production of nitric oxide, which is correlated with 
tumor angiogenesis, invasion, and metastasis. On the basis 
of this assumption, eNOS polymorphisms were retrospec-
tively investigated in 54 HCC patients receiving sorafenib. 
Patients carrying the b allele (five repetitions of 27 bp) of 
eNOS were found to have improved OS. The variants 4aa 
(four repeats of 27 bp in homozygosis), 4ab, and 4bb were 
associated with a median OS of 5.7 months, 13.9 months, 
and 23.6 months, respectively (P=0.016). For eNOS-786, the 
presence of the T allele was associated with a statistically 
significant, longer median OS (15.6 months vs 13.9 months, 
respectively; P=0.031).
Two Phase II randomized studies with novel antitumor 
agents were presented.24,25 Dovitinib was tested in patients 
with advanced HCC in an attempt to overcome the fibroblast 
growth factor receptors (FGFRs)-activated mechanism 
of resistance, which is considered an escape pathway for 
sorafenib activity. Nonetheless, dovitinib failed to prove 
superior to sorafenib in the first-line treatment of HCC. In the 
Phase II trial presented by Cheng et al24 OS was 34.6 weeks 
for dovitinib and 36.7 weeks (23.3 weeks–49.3 weeks) for 
sorafenib (HR: 1.27; 95% CI: 0.89–1.80). Palmer et al25 
presented disappointing results for the triple angiokinase 
inhibitor nintedanib. In a randomized Phase II trial, time 
to progression (TTP) was similar between nintedanib and 
sorafenib (TTP: 5.5 months vs 3.8 months; HR: 1.05; 95% 
CI: 0.63–1.76). Accordingly, median OS was similar between 
the treatment arms (11.9 months vs 11.4 months; HR: 0.88; 
95% CI: 0.52–1.47) (Table 1).25
Prajapati et al26 proposed a novel staging system for 
patients with advanced HCC treated with doxorubicin 
drug-eluting beads transarterial chemoembolization. In the 
multivariate analysis, the independent factors for survival 
were Child-Pugh class, ECOG PS, number of HCC lesions, 
index HCC (iHCC) size, site of portal or hepatic venous 
thrombosis, extrahepatic metastasis, and serum creatinine 
and AFP levels. Consequentially, the Clinical, Imaging, 
and Serum examination (CIS) staging system was proposed. 
According to the study findings, patients were grouped into 
different stages with different outcomes. The OS of stages I, 
II, III, and IV was 40.4 months, 24 months, 10.6 months, and 
2.6 months, respectively (P0.0001).
A prognosis model was also suggested for patients with 
locally advanced unresectable pancreatic cancer included 
in the LAP 07 trial.27 In the multivariate analysis, the inde-
pendent factors for OS were age, pain, albumin levels, and 
Response Evaluation Criteria in Solid Tumors (RECIST) 
size. Three risk groups were identified: lower risk (n=17; 
median OS: 18.8 months; group of reference); intermediate 
risk (n=166; median OS: 13.4 months); higher risk (n=187; 
median OS: 11.8 months). This easy-to-use prognostic model 
might be relevant for treatment decision in clinical practice 
and future trial design. Novel potential therapeutic options 
for metastatic pancreatic cancer have been suggested from 
analyses of randomized trials. In the three-arm NAPOLI-1 
trial,28 417 patients who had failed a gemcitabine-based 
first-line treatment were randomized to MM-398 (nanolipo-
somal encapsulation of irinotecan), 5-fluorouracil (FU) plus 
leucovorin (LV), or a combination of MM-398 and 5FU/LV. 
The primary end point of the trial was OS. The analysis in 
the per-protocol population (patients who received at least 
80% of the target dose in the first 6 weeks and did not violate 
any inclusion/exclusion criteria) confirmed the favorable 
OS, PFS, and ORR for the combination MM-398+5FU/LV 
arm relative to the control 5FU/LV arm with a manage-
able safety profile, whereas single-agent MM-398 was not 
superior to 5FU/LV.
A Phase I trial investigated the role of PF-04136309 
(a novel C–C chemokine receptor type 2 inhibitor) in com-
bination with FOLFIRINOX for locally advanced pancreatic 
cancer.29 Among 23 evaluable patients, 21 (91%) completed 
all six cycles; 12 (52.2%) obtained a RECIST-defined 
partial remission, whereas the remaining 11 (48%) had 
stable disease. Curative resections were achieved in four 
patients out of five with borderline resectable disease and 
in two with locally advanced pancreatic cancer. Globally, 
these very initial findings suggest that PF-04136309 and 
MM-398+5FU/LV should undergo further investigation in 
pancreatic cancer.
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Relevant information about the genomic landscape 
of biliary tract cancer was derived from an analysis 
including 500 hundred patients.30 The primary aim of 
the study was to identify crucial molecular markers as 
potential candidates for targeted agents. Findings from 
this analysis showed that intrahepatic cholangiocarcinoma 
(IHCCA), extrahepatic cholangiocarcinoma (EHCCA) and 
gall bladder carcinoma (GBCA) share genomic altera-
tions in cell cycle regulation (CDKN2B) and chromatin 
remodeling (ARID1A). IHCCA features FGFR fusions, 
isocitrate dehydrogenase (IDH)-1/2 substitutions, BRAF 
substitutions, and MET amplification, with a low KRAS-
mutation frequency. EHCCA and GBCA feature ERBB2 
amplifications (GBCA  EHCCA) and PIK3CA/MTOR 
pathway alterations. EHCCA has a high KRAS-mutation 
frequency, whereas the KRAS genomic alteration in GBCA 
is low. Knowledge of relevant genomic alterations will be 
a fundamental starting point in designing future clinical 
trials in this setting.
We believe that new data deriving from the 2015 Gastro-
intestinal Cancers Symposium on HCC, pancreatic cancer, 
and biliary tract cancer will serve as relevant integration to 
our scientific knowledge about this heterogeneous group of 
neoplasms. Although the search for novel therapeutic targets 
represents a priority in this setting, we should remember that 
an improvement in the use of already available treatment 
options is equally important.31,32 Recent presentation of 
results from an analysis of polymorphisms in the angiogenic 
pathway of HCC patients receiving sorafenib should be inte-
grated with already known data in this area and with clinical 
data defining prognostic groups.32,33 Similar considerations 
are applicable to data presented on patients with pancreatic 
cancer and biliary tract cancer.
Colorectal cancers: integrating novel 
drugs in innovative strategies
Results of the treatment with new antiangiogenic agents 
have been reported. Two studies suggested that ramuci-
rumab and famitinib might soon be added to the armamen-
tarium for metastatic CRC. The RAISE trial demonstrated 
that the addition of ramucirumab to second-line FOLFIRI 
chemotherapy resulted in a significant delay in disease 
progression and prolongation of survival in patients with 
metastatic CRC who had previously failed a first-line 
therapy containing bevacizumab.34 The study included 
1,072 patients with metastatic disease randomly assigned 
to ramucirumab (a human immunoglobulin G-1 monoclonal 
antibody that targets the extracellular domain of VEGFR2) 
plus FOLFIRI every 2 weeks per cycle (n=536) or placebo 
plus FOLFIRI every 2 weeks per cycle (n=536). The pri-
mary end point was OS. Ramucirumab reduced the risk for 
death by 16% (HR: 0.84; P=0.0219) and prolonged survival 
by a median of 1.6 months compared with FOLFIRI alone 
(median OS: 13.3 months vs 11.7 months). In addition, 
ramucirumab reduced the risk of disease progression by 
21% (HR: 0.79; P=0.0005).
The efficacy and safety of famitinib, a small multi-
target receptor tyrosine kinase inhibitor, which primarily 
inhibits VEGFR2, cKit, and PDGFR, were evaluated in a 
multicenter, randomized, double-blind, Phase II trial.35 The 
study included 154 advanced CRC patients, who were ran-
domly assigned in a 2:1 ratio to receive either famitinib or 
placebo. All patients had previously failed at least two lines 
of standard therapy. The primary end point was PFS. Fami-
tinib increased median PFS from 1.5 months to 2.8 months 
(HR: 0.58; 95% CI: 0.41–0.86; P=0.0034). No statistical 
difference was observed in median OS with famitinib vs 
placebo (7.5 months vs 7.6 months; HR: 1.10; 95% CI: 
0.76–1.60; P=0.605). The safety profile of famitinib was 
similar to that of other anti-VEGFR agents. Although these 
studies indicate that there will be alternative treatment 
options for metastatic CRC in the near future, they repre-
sent confirmations of the previously consolidated strategy 
of chemotherapy and antiangiogenic agent combination in 
unselected patients.36 During this edition of the conference, 
a significant convergence was also demonstrated in refining 
molecular selection to increase the effectiveness of targeted 
therapies and particularly in developing a “beyond-RAS” 
strategy;37 many works from all over the world have explored 
new screening, predictive biomarkers, and targeted therapies 
for metastatic CRC patients.
Preliminary data from two multinational screening plat-
forms show that collaborative genomic analysis beyond the 
RAS is feasible and might be used to run next-generation 
trials with targeted agents. The European Organisation for 
Research and Treatment of Cancer (EORTC) Screening 
Patients for Efficient Clinical Trial Access in advanced 
colorectal cancer (SPECTAcolor), a pan-European network, 
has already analyzed 406 patients in the first year and has 
planned to use next-generation sequencing for 360 key can-
cer alterations.38 A nationwide genomic screening project 
in Japan has evaluated a total of 361 tumor samples in the 
first 6 months to detect rare mutations such as PI3KCA and 
BRAF mutations.39
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Some other studies have shown that a strategy “from bench 
to bedside” is being pursued. The combination of the EGFR 
inhibitor panitumumab with the BRAF inhibitor vemurafenib 
for BRAF-mutant metastatic CRC has shown interesting 
hints of activity.40 Two of 12 evaluable patients (13%) had 
confirmed long-lasting partial responses, whereas 8 patients 
(53%) had stable disease. The combination was well toler-
ated, with acneiform rash, fatigue, and arthralgia being the 
most frequent treatment-related adverse events. On the basis 
of the same assumption that activation of the EGFR pathway 
is the leading cause of failure of anti-BRAF monotherapy, 
a randomized Phase II trial of irinotecan plus cetuximab with 
or without vemurafenib is also currently ongoing.41
Because another mechanism of resistance to anti-EGFR 
therapy is supposed to be HER2 amplification, in the Italian 
study HERACLES, heavily pretreated patients with HER2-
positive, EGFR inhibitor-refractory advanced CRC have been 
treated with the combination of lapatinib and trastuzumab.42 
As expected from the literature,43 the screening failure for 
HER2-positive patients was impressively high. Eighteen 
patients were enrolled (2.8% of the patients screened), and 
an ORR of 33% was achieved. Patients with HER2 3+ CRC 
and with a gene copy number 20 had the highest chance 
to respond to the dual inhibition.
Besides the new therapies and new strategies, the 2015 
Gastrointestinal Cancers Symposium challenged some old 
paradigms. A retrospective review of 145 patients with 
locally advanced rectal cancer who received standard 
neoadjuvant chemoradiation suggests that patients who 
obtained a clinical complete response can avoid surgery with 
little compromise in the overall outcomes.44 After a median 
follow-up of 3.5 years, there were no significant differences 
in disease-specific parameters or OS between patients who 
had a clinical complete response to preoperative therapy and 
skipped surgery on the one hand and patients who underwent 
rectal resection with a pathologic complete response (pCR) 
on the other. The study highlighted that a nonoperative 
approach may obtain preservation of rectal function in more 
than three-fourths of the patients.
The optimal timing of surgical resection of rectal cancer 
after preoperative chemoradiation was investigated in a ret-
rospective analysis of 6,805 patients in the National Cancer 
Database.45 A significant relationship between time delay (TD) 
and pCR was demonstrated (P=0.0002). At TD 30 days, 
4.0% of patients achieved pCR, while 9.3% of patients 
achieved pCR by 75 days. At TD 75 days, the rate of pCR 
decreased. However, TD of 60 days was associated with 
20% greater risk of mortality (95% CI: 1.07–1.36). Direct 
correlation between pCR and survival does not seem very 
strong in rectal cancer.
Conclusion
In the era of targeted therapies, trastuzumab and ramuci-
rumab are the only biologic therapy agents approved for 
patients with advanced gastroesophageal cancers, the first 
being limited for use in the 15% of patients with HER2- 
positive tumors. There is a need for novel agents to be offered 
to these patients. In this landscape, MET inhibitors fostered 
the debate, with discordant results: while onartuzumab 
and rilotumumab did not fulfill their promises, AMG 337 
provided interesting results. After several years of intense 
clinical and translational research, sorafenib still remains the 
only available therapeutic option for patients with advanced 
HCC. However, novel prognostic markers and interesting 
treatment strategies might, in the near future, change the way 
we approach this highly deadly disease. Besides TH-302, 
other novel drugs have emerged against pancreatic cancers. 
MM-398, an investigational nanocompound consisting of 
the chemotherapeutic irinotecan encapsulated in a liposomal 
sphere, and PF-04136309, a novel orally available human 
chemokine receptor 2 antagonist with immunomodulat-
ing and antineoplastic properties, may provide new hope 
for patients with advanced disease when combined with 
standard chemotherapy. With the expansion of the process 
of knowledge acquisition on CRC biology and, correspond-
ingly, of growth of complexity, famitinib and ramucirumab 
will provide new options to patients with advanced disease. 
Once again, many studies have been presented. Hopefully, 
the time needed to transfer these scientific advances to clini-
cal practice will be shorter than ever.
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